OBLN - Obalon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.8800
-0.0900 (-4.57%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.9700
Open1.9600
Bid1.8700 x 2200
Ask1.9500 x 1100
Day's Range1.8700 - 1.9800
52 Week Range1.5200 - 23.2800
Volume189,842
Avg. Volume331,300
Market Cap14.466M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Obalon Enters into a Distribution Agreement for Qatar

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a one-year agreement with Al Danah Medical Company (“Al Danah”) for distribution of the Obalon Navigation Balloon System in Qatar. Obalon has terminated its agreement with Bader Sultan and Bros. Company for distribution of its prior-generation balloons, which was set to expire on December 31, 2019.

  • GlobeNewswire

    Obalon To Present at Two Upcoming Institutional Investor Conferences

    SAN DIEGO, Nov. 14, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and.

  • GlobeNewswire

    Obalon Announces Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 08, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • GlobeNewswire

    Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019

    SAN DIEGO, Nov. 05, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • GlobeNewswire

    Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time

    SAN DIEGO, Oct. 31, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • GlobeNewswire

    Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that William J. Plovanic has been promoted to President and Chief Executive Officer, from his prior position of President and Chief Financial Officer. In conjunction with this change, Nooshin Hussainy, previously Vice President of Finance, has been promoted to the position of Chief Financial Officer. “In his prior role as President and CFO, Bill was instrumental in guiding the Company through its transition, galvanizing a new strategy to leverage our proprietary gastric-balloon weight loss system, and recapitalizing the business to fund the go-forward plan,” said Andy Rasdal, Executive Chairman of the Board of Directors at Obalon.

  • GlobeNewswire

    Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned weight loss treatment center, the Obalon Center for Weight Loss, in San Diego, California. The Obalon Center for Weight Loss is a medical facility staffed with physicians specializing in weight loss, nutritional counselors to help patients change their eating habits for sustainable weight loss, and other staff to help provide safe and effective treatment with the Obalon Balloon System.

  • GlobeNewswire

    Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that it has retired the remaining $5 million of its long-term debt facility with Pacific Western Bank. “We are pleased to continue to transform the Company’s financial position and believe that with no long-term debt and our current cash position we are well-positioned to drive our strategy to bring the Obalon Balloon System to patients in need of a proven weight loss solution,” said William J. Plovanic, President and Chief Financial Officer of Obalon.

  • GlobeNewswire

    Obalon Engages Helmuth T. Billy, MD as Medical Director for its First Company-Owned Weight Loss Treatment Center

    Leading bariatric surgeon and authority in the field to oversee medical activities for the Obalon Center for Weight Loss located in San Diego, CA. SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss announces that it has engaged Helmuth T. Billy, MD, as Medical Director to oversee medical affairs for the Company’s first weight loss treatment center.

  • GlobeNewswire

    Obalon Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

    SAN DIEGO, Aug. 05, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering

    Obalon Therapeutics Inc. (OBLN) (the “Company”), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced the pricing of an underwritten public offering of (i) 2,015,000 shares of common stock together with common stock warrants (the “common warrants”) to purchase 1,511,250 shares of common stock and (ii) 1,735,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 1,301,250 shares of common stock. The shares of common stock (or pre-funded warrants, as applicable) and accompanying common warrants are being sold together at a combined public offering price of $4.00 per share.

  • GlobeNewswire

    Obalon Announces Reverse Stock Split Effective Today

    Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has declared a 1-for-10 reverse stock split of the company’s common stock. The reverse stock split will become effective today, July 24, 2019 (the “Effective Date”). The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Global Market.

  • GlobeNewswire

    Obalon Announces Second Quarter 2019 Financial Results

    SAN DIEGO, July 24, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Enters Into Commercial Lease for its First Company-Owned Retail Weight Loss Center

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a commercial lease for its first Company-owned weight loss center. As part of a strategy to increase patient access and utilization of its novel gastric balloon weight loss system, Obalon intends to own and operate a network of retail centers throughout the United States that focus solely on patients wishing to lose weight using the Obalon Balloon System. “We are transitioning the business with the intent to create a network of Obalon retail centers in the United States, where patients can access our novel weight loss treatment in an environment dedicated to a standardized experience and achieve the most successful outcomes,” said Bob MacDonald, Obalon’s Chief Retail Officer.

  • GlobeNewswire

    Obalon Schedules Second Quarter 2019 Financial Results Conference Call for July 24, 2019 at 8:30 a.m. Eastern Time

    SAN DIEGO, July 22, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Obtains Two New U.S. Patents Covering Its Proprietary Intragastric Balloon System

    SAN DIEGO, July 16, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Strengthens Balance Sheet By Raising Additional Capital And Reducing Debt

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has reduced its outstanding debt under a facility with Pacific Western Bank from $20 million to $5 million. Throughout the second quarter of 2019, Obalon raised approximately $8.8 million in gross proceeds through a series of financings including a registered direct equity offering with A.G.P./Alliance Global Partners acting as our financial advisor, the sale of common stock through its equity line of credit with Lincoln Park Capital and an at-the-market (ATM) equity offering through Canaccord Genuity acting as sales agent.

  • GlobeNewswire

    Bariatric Medical Institute of Texas Presents Favorable Study Results for Obalon Balloon Administration Using Navigation Device and Touch Dispenser

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that substantial clinical data from a study conducted with 14 clinical sites was presented at Obesity Weekend in Chicago on Friday, June 21st 2019 by the study co-primary investigator, Michael V. Seger, MD, FACS, FASMBS, Bariatric Surgeon at Bariatric Medical Institute (San Antonio, TX). The co-primary endpoints of the Continuous Obalon Balloon Administration Location Tracking (COBALT) Study were met, with 100% correct decision-making for administering and inflating the Obalon Balloon System using the Navigation device instead of X-ray imaging.

  • GlobeNewswire

    Obalon Appoints Bob MacDonald as Chief Retail Officer

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces the appointment of Bob MacDonald to the newly created position of Chief Retail Officer. In this role, Mr. MacDonald will be primarily responsible for establishing Obalon-owned retail clinics focused on weight loss utilizing the Obalon Balloon System. “Bob’s outstanding experience in developing a successful national chain of aesthetic retail medical clinics for Sono Bello is a natural fit for Obalon, as we implement a retail-focused initiative to bring our proven weight loss solution to more patients,” said William J. Plovanic, Obalon’s President and Chief Financial Officer.

  • GlobeNewswire

    Obalon Announces Issuance of First U.S. Patent Covering Its Proprietary Navigation System

    SAN DIEGO, June 04, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Therapeutics, Inc. Prices $3,000,000 Registered Direct Offering

    OBALON THERAPEUTICS, INC. (OBLN) (“Obalon” or the “Company”), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced it has entered into definitive agreements with investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $0.60 per share, pursuant to a registered direct offering.  The gross proceeds of the offering will be approximately $3,000,000 before deducting fees and other estimated offering expenses. The Company intends to use the net proceeds for general corporate purposes, including, among other things, working capital, product development, capital expenditures, and other business opportunities.

  • GlobeNewswire

    Expanded Clinical Data Set for the Obalon Balloon System Presented at DDW 2019

    SAN DIEGO, May 21, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Announces Receipt of Delisting Notification Letters from Nasdaq

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it received two written notices from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") informing it that the Company is no longer in compliance with the Nasdaq Listing Rules. On May 15, 2019 the Company received a written notice from Nasdaq notifying the Company that it is not in compliance with Nasdaq Listing Rule 5450(b)(1)(A) based on the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2019, which reported the Company’s stockholders’ equity as $6,518,000, which is below the minimum of $10,000,000 in stockholders’ equity required for continued listing.

  • GlobeNewswire

    Obalon Engages Cowen to Explore Financial and Strategic Alternatives

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives.  As previously announced, Obalon recently undertook an organizational restructuring intended to refocus activities, streamline operations and make more efficient use of cash. With Cowen’s assistance, the Company plans to expand these efforts by exploring a wide range of financial and strategic alternatives that could enhance stockholder value and enable the Company to continue serving other important constituencies, including patients and physicians.

  • GlobeNewswire

    Obalon Announces Restructuring to Streamline Operations & Cash Use

    The Company expects the restructuring to reduce operating expenses in the second quarter of 2019 by approximately 35%, after one-time charges of approximately $1.0 million, when compared to the first quarter of 2019.  The changes reduce overall headcount by approximately 50%, including the elimination of Obalon’s direct field sales force and a reduction of headquarters staff.  As a result, the Company expects to transition to a new selling model intended to efficiently use the existing resources to develop the market and drive revenue.  The Company plans to provide more details related to its revised commercial structure and strategy, in addition to expectations around key metrics and updated financial guidance, on its first quarter 2019 earnings call in May. Dr. Huang continued, “The swallowable, gas-filled Obalon Balloon System continues to perform very well clinically, and we have seen accounts that commit to making Obalon a priority in their practice achieve strong results.